Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 71Terminated 21Active not recruiting 9Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 12Colorectal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 5Lung Neoplasms 4Triple Negative Breast Neoplasms 3Rectal Neoplasms 3Pancreatic Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia, Megakaryoblastic, Acute 3Fallopian Tube Neoplasms 3Stomach Neoplasms 2Ovarian Neoplasms 2Obesity 2Neoplasms 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Erythroblastic, Acute 2Leukemia, Eosinophilic, Acute 2Leukemia, Basophilic, Acute 2Hodgkin Disease 2Congenital Abnormalities 2Colonic Neoplasms 2Vulvar Neoplasms 1Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thymoma 1Sezary Syndrome 1Sertoli-Leydig Cell Tumor 1Salivary Gland Neoplasms 1

Interventions

3-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Has results × Neuroendocrine Tumors × Clear all
NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 2 Unknown
74 enrolled 10 charts 1 FDA
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡